Do Clinical Trial Results Hold Up in the Real World? A New Study on ALK+ Lung Cancer Says Yes—Mostly
Real-world claims data show alectinib beats crizotinib in ALK+ NSCLC survival, urging early use of newer ALK inhibitors.
Jorge Nieva, MD
Advertisement
Jorge Nieva, MD, is Associate Professor of Clinical Medicine at the Keck School of Medicine of USC.
Articles by Jorge Nieva, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
ASCO 2026 Breast Cancer Trials Affirm De-Escalation, Earlier Switching
2
Arlo-Cel Shows Promise in Early-Line Relapsed Multiple Myeloma
3
FDA Approves Capivasertib Plus Abiraterone and Prednisone for PTEN-Deficient Prostate Cancer
4
FAC-HCT Scale Integrating Frailty Stratifies Survival Before Allo-HCT
5